A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled MDT-637 in Healthy Volunteers.

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled MDT-637 in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Sep 2012

At a glance

  • Drugs MDT 637 (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Sep 2012 Results were presented at the 8th Annual International Respiratory Syncytial Virus Symposium (RSV-2012), according to a MicroDose Therapeutx media release.
    • 02 Dec 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
    • 02 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top